Candel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting
Candel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting
Candel Therapeutics 将在海丰国际年会上介绍 CAN-3110 在黑色素瘤中的临床前结果
- Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanoma
- CAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activation
- Findings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumo
- 在癌症免疫疗法学会（SITC）年会上被选为海报展示的摘要显示，CAN-3110 在黑色素瘤临床前模型中具有强大的抗肿瘤活性
- CAN-3110 的活性旨在以癌细胞中Nestin的表达为条件，并与溶瘤和免疫激活的双重活性有关
- 研究结果支持 CAN-3110 的潜在适应症从高级神经胶质瘤扩展为黑色素瘤，这是另一种表达 Nestin 的实体肿瘤
热门讨论
FOMC维持利率但不确定性高企：美股后市走向如何？
🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？
Moo Live
03/20 02:25
联邦公开市场委员会新闻发布会，2025年3月19日